Statistical Considerations for Clinical Trials During COVID-19: Steps for Mitigation
It is well-recognized that the COVID-19 pandemic has hit many ongoing clinical trials hard in many ways, including but not limited to:
- Government interventions including suppression and non-pharmaceutical interventions (NPIs) such as social distancing, lockdown, or quarantine.
- Supplies of study medications and availability of healthcare professionals and facilities for clinical and/or laboratory evaluations, treatment administration according to scheduled clinical visits typically specified in Table 1 of study protocols.
Liu, Qing, Karl E. Peace.
"Statistical Considerations for Clinical Trials During COVID-19: Steps for Mitigation."